- Alterity Therapeutics (NASDAQ:ATHE) announced that a study recently published in the journal Neurotherapeutics demonstrated that its lead clinical asset, ATH434, was neuroprotective in a genetic model of Parkinson’s disease (PD).
- The publication assessed the impact of ATH434 on motor and non-motor deficits in mice with genetically induced Parkinson’s disease.
- Hyposmia, defined as reduced sensitivity to odor, is an early and common non-motor symptom of PD that precedes the typical motor symptoms by several years, occurring in approximately 90% of early-stage cases of PD2.
- The study found that ATH434 prevented a loss of smell in the younger mice and rescued it in older mice.
- The authors also demonstrated that ATH434 prevented the development of motor impairment in older animals, which was associated with a reduction in iron levels and preservation of neurons in the substantia nigra, the brain region affected in Parkinson’s.
- These data support other studies indicating that ATH434 has a beneficial effect on motor and non-motor symptoms in animal models of PD.
- Price Action: ATHE shares are up 8.95% at $4.26 on the last check Monday.
Cowen, Evercore ISI See Huge Upside In This S&P 100 Constituent
Cowen analyst Matt Elkott initiated Caterpillar Inc. (NYSE:CAT) with an Outperform rating and a price target of $241, implying an upside of 24%.…
